Usage of Radiotherapy With Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations

We read with interest the results of the WJOG9717L phase 2 randomized trial by Kenmotsu et al., 1 Kenmotsu H. Wakuda K. Mori K. et al. Randomized phase 2 study of osimertinib plus bevacizumab versus osimertinib for untreated patients with nonsquamous NSCLC harboring EGFR mutations: WJOG9717L study. J Thorac Oncol. 2022; 17: 1098-1108 Abstract Full Text Full Text PDF PubMed Scopus (27) Google Scholar wherein the addition of bevacizumab to osimertinib in previously untreated patients with EGFR-positive nonsquamous NSCLC was found to have no progression-free survival benefit. The authors should be congratulated on this well-designed trial with robust intention-to-treat analysis, with results that further knowledge on EGFR and vascular endothelial growth factor inhibitor combinations. With progression-free survival beyond 20 months in both study arms and median overall survival unreached, the trial supports existing data of prolonged survival with osimertinib in this population. Although grade ≥3 toxicity was higher in the bevacizumab arm (56% versus 48%), the rate of any-grade pneumonitis was lower (3% versus 18%), with no differences in grade ≥3 pneumonitis (2% in both arms). Response to “Letter to the Editor” From David Y. Mak et alJournal of Thoracic OncologyVol. 18Issue 1PreviewWe thank Mak et al. for their letter to the editor in response to our recent article entitled “Randomized phase II study of osimertinib plus bevacizumab versus osimertinib for untreated patients with nonsquamous non–small cell lung cancer harboring EGFR mutations: WJOG9717L study” published in the Journal of Thoracic Oncology.1 Full-Text PDF